In this issue:
Anti-TL1A monoclonal antibody (tulisokibart) for UC
Anti-mycobacterial triple therapy in active CD
Mesenteric sparing vs. extended resection in primary ileocolic resection of CD
PSC and IBD prevalence in England: 2015–2027
Risankizumab for UC
IBD phenotypes in Māori New Zealanders
Predicting intravenous corticosteroid failure in acute UC
Impact of prepregnancy IBD surgery on maternal/fetal outcomes
AI for quantifying cumulative small-bowel disease severity on CT-enterography in CD
Switching from intravenous to subcutaneous vedolizumab for IBD
Please login below to download this issue (PDF)